Literature DB >> 13977

Metabolic fate of phenobarbital. A quantitative study of p-hydroxyphenobarbital elimination in man.

M P Whyte, A S Dekaban.   

Abstract

Biotransformation of phenobarbital (PB) to p-hydroxyphenobarbital (PHPB) was studied quantitatively by gas-liquid chromatography in 8 epileptic patients who were receiving an established regimen of antiepileptic drugs including PB. PB and both conjugated and unconjugated PHPB were present in each patient's urine; m-hydroxyphenobarbital (MHPB) was not detected despite an assay sensitivity of 0.25 mug/ml. Incubation of the urine with beta-glucuronidase, but not with arylsulfatase, liberated PHPB which was, therefore, presumed to be conjugated with glucuronic acid. In general, the patients' urine contained more PB than total PHPB. Recovery of the patients' total daily dose of PB ranged from 24 to 77% (mean, 42%). After receiving a single iv dose of PB, PB and both conjugated and unconjugated PHPB were found in a normal volunteer's urine throughout a 16-day collection period; 30% of the dose was recovered. PB excretion was proportional to urine volume in the volunteer and in two additional patients who were made to vary their daily fluid intake. PHPB was not detected in the cerebrospinal fluid of 10 patients receiving PB. Neither PB, PHPB, nor MHPB were detected in the feces of four patients. These results suggest that metabolites other than PHPB or MHPB may be important in the elimination of PB in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 13977

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 2.  Dose-related adverse effects of anticonvulsants.

Authors:  A S Troupin
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

3.  Urinary excretion of phenobarbital and its metabolite p-hydroxyphenobarbital in convulsing and non-convulsing patients.

Authors:  B Brzakovic; M Pokrajac; E Dzoljic; Z Levic; V M Varagic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.441

4.  Phenobarbital-induced alterations in the metabolism of [3H]vitamin D3 by the perfused rachitic rat liver in vitro.

Authors:  D T Baran; A C Fausto; M L Roberts; I Karl; L V Avioli
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

6.  Inhibition of phenobarbitone N-glucosidation by valproate.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

7.  Urinary excretion of phenobarbitone and its metabolites in chronically treated patients.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.